VJHemOnc is committed to improving our service to you

ESH AL 2020 | Allogeneic HSCT in patients with high-risk myeloma

VJHemOnc is committed to improving our service to you

Sergio Giralt

Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial, which compared tandem autologous transplant (auto-auto) versus autologous followed by reduced-intensity allogeneic (auto-allo) transplant in patients with newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter